This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Uloric (febuxostat) is a medication prescribed to lower uric acid levels in individuals with gout. Gout is a type of arthritis that occurs when a naturally occurring substance in the body known as uric acid builds up, causing sudden attacks of redness, swelling, and pain in joints. Approved for sale by the FDA in February 2009, Uloric is intended to lower uric acid levels in the bloodstream.
Upon initial FDA approval of Uloric, the FDA included a Warning and Precaution concerning cardiovascular events due to clinical trials conducted prior to the approval of the drug showing a higher rate of heart-related problems in patients treated with Uloric, as compared to alternative gout medication, allopurinol. These problems included heart attacks, strokes, and heart-related deaths.
As a result of these clinical trials, on February 21, 2019, the FDA required Takeda to update the Uloric labeling with a Black Box Warning about the increased risk of cardiovascular issues.
The FDA advises patients: Do not stop taking Uloric without first talking to your health care professional, as doing so can worsen your gout.
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.